CSIMarket


Ocuphire Pharma Inc   (OCUP)
Other Ticker:  
 


 

Ocuphire Pharma Inc

OCUP's Financial Statements and Analysis



Ocuphire Pharma Inc reported in the third quarter of 2023 net earnings per share of $0.25 an improvement compare to net loss per share of $-0.22 recorded a year ago and an improvement compare to net loss per share of $-0.24 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ 0.25 $  12 Mill
$+0.47     $+12M    



Ocuphire Pharma Inc 's Revenue rose by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $12 million and advanced by 224.85 % sequentially.


Ocuphire Pharma Inc is Expected to report next financial results on March 29, 2024.

More on OCUP's Income Statement



Ocuphire Pharma Inc 's net income of $5.561 million in the third quarter of 2023 increased from net loss of $-4.531 million III. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-4.961 million recorded in previous quarter.

More on OCUP's Growth

Ocuphire Pharma Inc Inventories
OCUP's Cash flow In the third quarter of 2023 company's net cash flow was $2 million


Ocuphire Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Ocuphire Pharma Inc earned $ 1.03 cash per share, on a free-cash flow basis 105.34 % of net earning per share.

Book value grew by 24.75 % sequentially to $2.24 per share, 169.23% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 2.24 per share from $ 1.80.

Company issued 1.45 million shares or 6.90 % in Sep 30 2023.
Interest Coverage Ratio was 1.6762902216231E+19.

More on OCUP's Dividends

 Market Capitalization (Millions) 45
 Shares Outstanding (Millions) 22
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) 29
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Ocuphire Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Ocuphire Pharma Inc had $ 1.03 cash flow per share, on a free-cash flow basis 105.34 % of net earning per share.

Book value grew by 24.75 % sequentially to $2.24 per share, 169.23% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 2.24 per share from $ 1.80.

Company issued 1.45 million shares or 6.90 % in Sep 30 2023.
Interest Coverage Ratio was 1.6762902216231E+19.

More on OCUP's Balance Sheets

 Market Capitalization (Millions) 45
 Shares Outstanding (Millions) 22
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) 29
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Ocuphire Pharma Inc Earnings

Ocuphire Pharma Inc. Records Impressive Revenue of $3.674 Million in Q2 of 2023

Ocuphire Pharma Inc, a leading pharmaceutical company, has reported its financial results for the second quarter of 2023. The company generated $3.674 million in revenue during this period, indicating a positive growth trajectory. However, Ocuphire Pharma also recorded a net shortfall of $-4.961 million, which was slightly larger than the $-4.927 million shortfall experienced in the same quarter last year. This suggests that the company still faces financial challenges and needs to address its expenses.
Investors and analysts are eagerly waiting for the next financial update from Ocuphire Pharma Inc, which is scheduled to be released on November 03, 2023. This report is expected to provide a clearer pict...

Ocuphire Pharma Inc Reports $1.749 Million in Q1 2023 Revenue, Showing Solid Financial Progress Amidst $5.791 Million Net Deficit

As a journal...


Date modified: 2023-11-14T21:09:11+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com